Trials / Completed
CompletedNCT00511511
Angiogenesis Inhibitors and Hypertension: Clinical Aspects
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to find simple clinical and laboratory parameters to predict the development of hypertension and to elucidate the mechanism of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib.
Detailed description
Inhibition of angiogenesis with antibodies against vascular endothelial growth factor (VEGF) and VEGF receptor antagonists has become an established treatment for cancer. An unanticipated side effect of angiogenesis inhibitors is the development of hypertension. The pathogenesis of this hypertension is unknown. Not all patients will develop hypertension. However, it is not known which patient will and which patient will not develop hypertension.
Conditions
Timeline
- Start date
- 2007-08-01
- Completion
- 2009-12-01
- First posted
- 2007-08-06
- Last updated
- 2010-01-05
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00511511. Inclusion in this directory is not an endorsement.